"With more than 300 physicians, 50 medical specialties, 15 surgical services, and compassionate preventive and primary care, MassGeneral Hospital for Children is an invaluable resource for the health-care needs of infants, children and adolescents."

During the past decade, Massachusetts General Hospital for Children conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 5 clinical trials were completed, i.e. on average, 35.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Massachusetts General Hospital for Children" #1 sponsor was "Massachusetts General Hospital" with 4 trials, followed by "bluebird bio" with 4 trials sponsored, "University of Alabama at Birmingham" with 3 trials sponsored, "Duke University" with 1 trials sponsored and "Michael Cotten" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Massachusetts General Hospital for Children" #1 collaborator was "Azienda Sanitaria Locale Salerno" with 1 trials as a collaborator, "Childhood Arthritis and Rheumatology Research Alliance" with 1 trials as a collaborator, "Children's Hospital Medical Center, Cincinnati" with 1 trials as a collaborator, "Crohn's and Colitis Foundation" with 1 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Massachusetts General Hospital for Children" are "Cerebral Adrenoleukodystrophy (CALD)" (4 trials), "Adrenoleukodystrophy (ALD)" (2 trials), "Lennox Gastaut Syndrome" (2 trials), "NF1" (2 trials) and "X-Linked Adrenoleukodystrophy (X-ALD)" (2 trials). Many other conditions were trialed in "Massachusetts General Hospital for Children" in a lesser frequency.

Most popular intervention types in "Massachusetts General Hospital for Children" are "Drug" (6 trials), "Genetic" (4 trials), "Device" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Allo-HSCT" (1 trials), "Bevacizumab" (1 trials), "Cabozantinib" (1 trials), "Control Group" (1 trials) and "INFUSE Bone Graft (BMP-2)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Massachusetts General Hospital for Children" are 14 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Massachusetts General Hospital for Children". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 6 completed trials in Massachusetts General Hospital for Children, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Massachusetts General Hospital for Children, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".